Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV Busulfan With Bortezomib Followed by Autologous HSCT in Relapsed Multiple Myeloma
NCT01009840Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- May 2010
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of busulfan in multiple myeloma (MM), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started May 2010; status: completed.
02
Drugs
busulfan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01009840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01009840.